Skip to main content
. 2022 Jul 29;14(15):3703. doi: 10.3390/cancers14153703

Table 3.

Multi-step validations proposed to assess LCO purity. SCLC, small-cell lung cancer; NSCLC, non-small-cell lung cancer; H&E, hematoxylin/eosin staining; CK7, Cytokeratin 7; CK5/6, Cytokeratin 5/6; TTF-1, Thyroid Transcription Factor-1; CD56, cluster of differentiation 56, IHC, immunohistochemistry. The table reports information [16,40].

LCOs VALIDATIONS
HISTOMORPHOLOGY IHC GENETIC XENOGRAFT FORMATION
NSCLC ADENOCARCINOMA Solid or cystic

Inline graphic 		H&E
NAPSIN
TTF-1
CK7		 COPY NUMBER

LUNG CANCER-RELATED MUTATIONS

WHOLE EXOME SEQUENCING
Inline graphic 		graphic file with name cancers-14-03703-i003.jpg
ADENOSQUAMOUS CARCINOMA H&E
CK7
CK5/6
p63
SQUAMOUS CELL CARCINOMA H&E
p63
TTF-1
CK5/6
SCLC SMALL CELLCARCINOMA H&E
CD56
TTF-1
Synaptophysin